Abstract:Parkinson’s disease arises from the demise of dopaminergic neurons in the substantia nigra resulting from both environmental and hereditary factors. Drug interventions can solely delay disease progression, but cannot provide a cure. Therefore, cell replacement therapy may represent a promising treatment approach. Although the United States has already employed this technology, independent clinical and preclinical trials are mandatory for its inclusion in Russia. The iPSC technology enables the acquisition of personalized iPSC lines for each patient, nearly eradicating the immune response. While autologous cell therapy is theoretically ideal, the reprogramming of patient cells into iPSCs and subsequent differentiation for each patient incurs time and cost. Alternatively, differentiated derivatives of low immunogenic iPSCs, lacking HLA class I expression, can serve as a substitute. These cells evade the T-cell immune response, but other minor HLAs and cells from the innate immune system, like macrophages and NK cells, could still participate in the immune response’s development, although not as potent as in allogeneic transplantation. While these cell products don’t escape the immune response entirely, they lessen it significantly, potentially enabling the use of less severe immunosuppressive therapy. In this study, a protocol previously established in the cell biology laboratory was used to differentiate iPSCs lacking HLA class I expression and wild-type iPSCs into midbrain dopaminergic neuron precursors. A thorough analysis of the forerunners was performed and demonstrated appropriate patterning. The progenitors were then implanted into the brains of rats with 6-OHDA-induced Parkinsonism and followed for 6 months to compare their in vivo differentiation to standard differentiation in vitro. In addition, the systemic inflammatory response of the animals to the transplantation and the biodistribution of the injected cells were investigated. The literature inadequately addresses the question of which cells, other than dopaminergic neurons, differentiate during in vivo graft differentiation and potentially cause side effects in cell therapy. The literature suggests that only approximately 3% of transplanted cells differentiate into dopaminergic neurons, which is adequate to improve motor function in model animals. We found that a significant proportion of the progenitors differentiate into glial cells. The dynamics of maturation of transplanted neurons was evaluated. Thus, we approached preclinical testing of the cell product after having characterized in detail the dynamics of maturation and the composition of the graft. Comparison of in vivo and in vitro differentiation will allow evaluation of the quality of cellular material for transplantation.

Infusion of epidermal growth factor and basic fibroblast growth factor into the striatum of parkinsonian rats leads to in vitro proliferation and differentiation of adult neural progenitor cells.

Title Efficient derivation of dopaminergic neurons from SOX 1 (-) floorplate cells under defined culture conditions

Distinct Efficacy of Pre-Differentiated Versus Intact Fetal Mesencephalon-Derived Human Neural Progenitor Cells in Alleviating Rat Model of Parkinson’s Disease

Neural Stem/progenitor Cells Survive and Differentiate Better in PD Rats Than in Normal Rats.

Dopamine Release from Transplanted Neural Stem Cells in Parkinsonian Rat Striatum in Vivo.

Differentiation of Adult Human Retinal Pigment Epithelial Cells into Dopaminergic-Like Cells in Vitro and in the Recipient Monkey Brain

Therapeutic function of iPSCs-derived primitive neuroepithelial cells in a rat model of Parkinson's disease

Co-Transplantation of GDNF-Overexpressing Neural Stem Cells and Fetal Dopaminergic Neurons Mitigates Motor Symptoms in a Rat Model of Parkinson’s Disease

Green fluorescent protein-labeled mapping of neural stem cells migrating towards damaged areas in the adult central nervous system.

Rescue Of Dopamine Release And Behavior By Transplanted Neural Stem Cells In A Rat Model Of Parkinsonism

Dental Follicle Cells Show Potential for Treating Parkinson's Disease Through Dopaminergic-Neuronogenic Differentiation.

Puerarin promoted proliferation and differentiation of dopamine-producing cells in Parkinson's animal models

Mesencephalic Progenitors Can Differentiate into TH-Positive Neurons and Improve Dysfunction in PD Rats

In Vitro Culture and Differentiation of Rat Embryonic Midbrain-Derived Neural Stem Cells

Differentiation and proliferation patterns of neural stem cells of astrocyte origin in the rat spinal cord

Selective Generation of Dopaminergic Precursors from Mouse Fibroblasts by Direct Lineage Conversion

Bridging Nigrostriatal Pathway with Fibroblast Growth Factor-Primed Peripheral Nerves and Fetal Ventral Mesencephalon Transplant Recuperates from Deficits in Parkinsonian Rats

Dopaminergic progenitors generated by small molecule approach survived, integrated, and promoted functional recovery in (6-OHDA) mouse model of Parkinson's disease

Therapeutic function of a novel rat induced pluripotent stem cell line in a 6‑OHDA‑induced rat model of Parkinson's disease

Mesencephalic progenitors can improve rotational behavior and reconstruct nigrostriatal pathway in PD rats

The fate of iPSCs-derived low immunogenic dopaminergic neuron precursors after transplantation into the striatum of rats with 6-OHDA-induced parkinsonism